FDA ques­tions off-tar­get ed­it test­ing on Ver­tex and CRISPR's po­ten­tial sick­le cell gene ther­a­py ahead of ad­comm

The FDA is con­ven­ing an ad­vi­so­ry com­mit­tee next Tues­day to dis­cuss whether Ver­tex Phar­ma­ceu­ti­cals and CRISPR Ther­a­peu­tics did enough to ad­e­quate­ly mea­sure the off-tar­get al­ter­ations …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER